Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sonelokimab (ALX 0761; M 1095) is a trivalent nanobody that combines monovalent camelid-derived nanobodies targeting human interleukin (IL)-17A and IL-17F, along with human serum albumin VHHs. This composition presents sonelokimab as a promising candidate for the investigation of plaque-type psoriasis treatments [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Sonelokimab (ALX 0761; M 1095) is a trivalent nanobody that combines monovalent camelid-derived nanobodies targeting human interleukin (IL)-17A and IL-17F, along with human serum albumin VHHs. This composition presents sonelokimab as a promising candidate for the investigation of plaque-type psoriasis treatments [1] [2]. |
Molecular Weight | N/A |
CAS No. | 1414386-05-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Sonelokimab 1414386-05-2 inhibitor inhibit